Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

The parotid gland; an unusual site of colorectal cancer metastasis

ASCO's efforts to improve global cancer care through the years

US NCI's global health initiatives at ASCO 2023

Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine improves PFS in N2-3 nasopharyngeal carcinoma

Talazoparib plus enzalutamide shows improvement in PFS over standard of care in firstline HRR mCRPC

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC

Extended lymph node removal does not benefit patients with clinically localised muscle-invasive bladder cancer

Dostarlimab chemo combination for primary advanced or recurrent endometrial cancer

2L triple metronomic chemo shows more efficacy in comparison to systemic therapy for head and neck cancer

ASCO 2023: Breast cancer research highlights